Development of a rapid HPLC method for determination of famotidine in human plasma using a monolithic column

A rapid and sensitive HPLC method using a monolithic column has been developed for quantification of famotidine in plasma. The assay enables the measurement of famotidine for therapeutic drug monitoring with a minimum detectable limit of 5 ngml(-1). The method involves simple, one-step extraction procedure and analytical recovery was complete. The separation was carried out in reversed-phase conditions using a Chromolith Performance (RP-18e, 100 mm x 4.6 mm) column with an isocratic mobile phase consisting of 0.03 M disodium hydrogen phosphate buffer-acetonitrile (93:7, v/v) adjusted to pH 6.5. The wavelength was set at 267 nm. The calibration curve was linear over the concentration range 20-400 ngml(-1). The coefficients of variation for inter-day and intra-day assay were found to be less than 8%.     

Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies

A simple, rapid and sensitive isocratic reversed-phase HPLC method with fluorescence detection using a monolithic column has been developed and validated for the determination of carvedilol in human plasma. The separation was performed on a Chromolith Performance (RP-18e, 100mm x 4.6mm) column with an isocratic mobile phase consisting of 0.01 M disodium hydrogen phosphate buffer-acetonitrile (40:60, v/v) adjusted to pH 3.5. The sample preparation involves protein precipitation procedure and analytical recovery was complete. Letrozole was used as internal standard. The assay enables the measurement of carvedilol for therapeutic drug monitoring with a minimum quantification limit (LOQ) of 1 ng ml(-1). The excitation and emission wavelengths were set at 240 and 340 nm, respectively. The calibration curve was linear over the concentration range 1-80 ng ml(-1). The coefficients of variation for inter-day and intra-day assay were found to be less than 8.0%.     

HPLC determination of omeprazole in human plasma using a monolithic column

A rapid and sensitive HPLC method using a monolithic column has been developed for quantification of omeprazole (CAS 73590-58-6) in plasma. The method was specific and sensitive with a quantification limit of 10 ng/ml. Sample preparation involves simple, one-step extraction procedure and analytical recovery was complete. The separation was carried out in reversed-phase conditions using a Chromolith Performance (RP-18e, 100 x 4.6 mm) column with an isocratic mobile phase consisting of 0.01 mol/l disodium hydrogen phosphate buffer-acetonitrile (73:27 v/v) adjusted to pH 7.1. The wavelength was set at 302 nm. The calibration curve was linear over the concentration range 20-1500 ng x ml(-1). The coefficients of variation for inter-day and intra-day assay were found to be less than 7%.     

Simultaneous determination of amoxicillin and clavulanic acid in human plasma by isocratic reversed-phase HPLC using UV detection

A simple, rapid and sensitive isocratic reversed phase HPLC method with UV detection using internal standard has been developed and validated for simultaneous determination of amoxicillin and clavulanic acid in human plasma. The assay enables the measurement of amoxicillin and clavulanic acid for therapeutic drug monitoring with a minimum quantification limit of 15 and 30 ng ml(-1), respectively. The method involves simple, one-step extraction procedure and analytical recovery was complete. The separation was carried out in reversed-phase conditions using a Chromolith Performance (RP-18e, 100 mm x 4.6mm) column with an isocratic mobile phase consisting of 0.02 M disodium hydrogen phosphate buffer-methanol (96:4, v/v) adjusted to pH 3.0. The wavelength was set at 228 nm. The coefficients of variation for inter-day and intra-day assay were found to be less than 9.0%.     

A rapid HPLC method for the determination of losartan in human plasma using a monolithic column

A rapid and simple high-performance liquid chromatography (HPLC) method using a monolithic column has been developed for quantification of losartan (CAS 12450-98-8) in plasma. The assay enables the measurement of losartan for therapeutic drug monitoring. The method involves a simple, one-step extraction procedure. The analytical recovery was complete. The separation was carried out in reversed-phase conditions using a Chromolith Performance (RP-18e, 100 x 4.6 mm) column with an isocratic mobile phase consisting of 0.01 mol/L disodium hydrogen phosphate buffer-acetonitrile (60:40 v/v) adjusted to pH 3.5. The wavelength was set at 254 nm. Thioridazine (CAS 50-52-2) was used as internal standard. Losartan, thioridazine and the EXP 3174, the active metabolite of losartan, appeared 3.4, 5.0 and 10.5 min post injection, respectively. The calibration curve was linear over the concentration range 5-300 ng mL(-1) with a minimum detectable limit of 2 ng mL(-1). The coefficients of variation for the inter-day and intra-day assay were found to be less than 8 %. The applicability of this method for pharmacokinetic studies in humans was demonstrated. The present assay is rapid, simple, precise, and accurate and is suitable for pharmacokinetic studies.     

High-performance liquid chromatography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: application to a pharmacokinetic study in the Chinese volunteers

This study presents a rapid, specific and sensitive LC-MS/MS assay for the determination of ramipril and ramiprilat in human serum using enalapril as an internal standard (IS). A Waters Atlantis C18 column (2.1 mm x 100 mm, 3 microm) and a mobile phase consisting of 0.1% formic acid-methanol (25:75, v/v) were used for separation. The analysis was performed by the selected reaction monitoring (SRM) method, and the peak areas of the m/z 417.3-->234.3 and m/z 389.3-->206.2 transition for ramipril and ramiprilat, respectively, were measured versus that of the m/z 377.3-->234.2 for IS to generate the standard curves. The assay linearities of ramipril and ramiprilat were confirmed over the range 0.10-100 ngml(-1) and 0.25-100 ngml(-1), respectively, and limits of quantitation for them were 0.10 and 0.25 ngml(-1), respectively. The linear ranges correspond well with the serum concentrations of the analytes obtained in clinical pharmacokinetic studies. Intraday and interday relative standard deviations of ramipril and ramiprilat were 2.8-6.4% and 4.3-4.6%, 4.4-6.7% and 3.5-4.7%, respectively. The recoveries of ramipril and ramiprilat from serum were in the range of 81.0-98.2%. The developed LC-MS procedures were applied for the determination of the pharmacokinetic parameters of ramipril and ramiprilat following a single oral administration of 10mg ramipril tablets in 18 Chinese healthy male volunteers.     

Quantification of gliclazide by semi-micro high-performance liquid chromatography: application to a bioequivalence study of two formulations in healthy subjects

The objective of the present study was to evaluate the bioequivalence of two formulations of gliclazide in healthy human volunteers. Bioequivalence of the two formulations was determined in 20 healthy subjects with a single-dose, two-period, crossover study. A new high-performance liquid chromatographic method for the pharmacokinetic analysis of gliclazide was developed, using a semi-micro column to quantify gliclazide in plasma samples. Chromatographic separation was achieved with a semi-micro C18 column and 40 mM KH2PO4 (pH 4.6)-acetonitrile-isopropyl alcohol (5:4:1, v/v/v) as the mobile phase, and with UV detection at 229 nm. The method displayed good precision (coefficients of variation (CV < 8.0%)), was fast (total analysis time 8 min), and required only a small amount of mobile phase (0.22 ml/min), with a reasonable limit of quantification (0.1 microg/ml). The calibration curve was linear in the concentration range 0.1-10 microg/ml. When the pharmacokinetic parameters of gliclazide in the two formulations were calculated and compared statistically using crossover analysis of variance, they were similar, with no statistically significant difference. Ninety percent confidence intervals for AUC0-last, AUC0-infinity, and Cmax, used to evaluate bioequivalence, were in the stipulated range of 0.80-1.25. This result suggests that two formulations are bioequivalent when administered orally at a dose of 80 mg gliclazide.     

HPLC法测定犬血浆中格列奇特的浓度

目的建立犬血浆中格列齐特浓度的HPLC测定法。方法采用色谱柱为Nucleodur C18硅胶柱(250×4.6mm,5um);流动相为磷酸盐缓冲液(pH2.5)-甲醇(40∶60,v/v);流速1.0mL/min;检测器波长228nm;以甲苯磺丁脲为内标。结果格列齐特浓度在0.125~16μg/mL范围内线性关系良好(r=0.9999),最低检测浓度为0.10ug/mL,日间及日内RSD均小于8%,平均萃取回收率合为79.98%。结论本法操作简便、快速、灵敏度高,可用于格列齐特药代动力学研究。     

Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection

A simple high-performance liquid chromatography method for the determination of the human immunodeficiency virus protease inhibitor atazanavir in human plasma samples was developed and validated. The method involved a rapid and simple solid-phase extraction of atazanavir using Oasis HLB 1cc cartridges, an isocratic reversed-phase liquid chromatography on an XTerra RP18 (150mmx4.6mm, 3.5microm) column, and ultraviolet detection at 203nm. The mobile phase consisted of phosphate buffer (pH 6, 52.5mM) and acetonitrile (43:57, v/v). Up to 48 samples could be measured in one day since the run-time of one sample was 30min. The assay was linear from 0.04 to 10microg/ml with a lower limit of quantification of 0.04microg/ml. The mean absolute recovery of ATV was 98.1%. The method was precise, with both intra-day and inter-day coefficients of variation < or =3.0%, and accurate (deviations ranged from -3.0% to 4.5% and from -3.6% to 4.7% for intra-day and inter-day analysis, respectively). There was no interference from 35 tested potentially co-administrated drugs. This method provides a simple, sensitive, precise and reproducible assay for the therapeutic drug monitoring of atazanavir in clinical routine of laboratories with standard equipment.     

A simple HPLC method using a microbore column for the analysis of doxorubicin

Doxorubicin is one of the most potent anti-tumor agents generally used in the treatment of bone cancer. A simple and sensitive HPLC method was developed and validated for the assay of doxorubicin. The method used a C18 Luna microbore column (50 x 1 mm) with a fluorescent detector (505 nm Ex. and 550 nm Em.). The mobile phase consisted of water-acetonitrile-acetic acid (80:19:1, v/v/v, pH 3.0) and the flow rate was 0.1 ml min(-1). Daunomycin was used as the internal standard. This isocratic system required a 10-min run-time, giving a detection limit of 0.02 ng (0.035 pmol per injection). Standard curves were linear over the concentration range of 0.01-0.1 microg ml(-1). Relative standard deviations (R.S.D.) for the within-day, day-to-day precision, and the accuracy measurement for the assay were less than 4.0, 3.2, and 4.1%, respectively. This HPLC method was used to study the in vitro release characteristics of doxorubicin from implantable drug delivery system.     

Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs,metformin and gliclazide

An efficient and simple HPLC method has been developed and validated for the simultaneous determination of gliclazide and metformin hydrochloride in bulk and was applied on marketed metformin and gliclazide products. The mobile phase used for the chromatographic runs consisted of 20 mM ammonium formate buffer (pH 3.5) and acetonitrile (45:55, v/v) The separation was achieved on an Alltima CN (250 mm × 4.6 mm x5μ) column using isocratic mode. Drug peaks were well separated and were detected by a UV detector at 227 nm. The method was linear at the concentration range 1.25–150 μg/ml for gliclazide and 2.5–150 μg/ml for metformin respectively. The method has been validated according to ICH guidelines with respect to system suitability, specificity, precision, accuracy and robustness. Metformin limit of detection (LOD) and limit of quantification (LOQ) were 0.8 μg/ml and 2.45 μg/ml respectively while LOD and LOQ for gliclazide were 0.97 μg/ml and 2.95 μg/ml respectively.     

LC-ESI-MSD fast determination of residual mitomycin C in hen aqueous humour after corneal refractive surgery

A simple, fast and reliable method has been developed for the assay of traces of mitomycin C (MMC) in hen aqueous humour samples. The determination was carried out by high-performance liquid chromatography with electrospray ionization mass spectrometric detection. In isocratic elution analysis, the mobile phase was a mixture of water-acetonitrile (78:22, v/v) and the chromatographic column was C(18) at 35 degrees C. The method has been validated over a range from 0.1 to 250 microg L(-1) in hen aqueous humour with correlation coefficients higher than 0.999. Limit of detection and limit of quantification for MMC based in signal to noise ratio of 3 and 10, respectively, were 20 and 71 ng L(-1). The developed method allows the analysis of MMC in hen aqueous humour samples obtained at different times and conditions in order to evaluate and compare the efficacy of the drug administration.     

A rapid HPLC/ESI-MS method for the quantitative determination of oridonin in rat plasma

A rapid and accurate method using liquid chromatography with electrospray ionization mass spectrometric detection (HPLC/ESI-MS) was developed and validated for the determination of oridonin in rat plasma. The analytes were extracted with ethyl acetate-n-butyl alcohol (100:2, v/v) after spiking the samples with ethyl hydroxybenzoate (internal standard). The separation was carried out on a Diamon-sil C18 column with an isocratic mobile phase consisting of methanol-water (80:20, v/v) at a flow rate of 1.0 ml/min. The lower limit of quantification (LLOQ) of the method was 10 ng/ml and the linear range was 10-4000 ng/ml. The intra-day and inter-day accuracy and precision of the assay were less than 9%. This method has been applied successfully to a preliminary pharmacokinetic study involving the intravenous administration of oridonin to rats.     

Method development and validation for the HPLC potency assay of troglitazone tablets

This paper describes the development and validation of an isocratic, reversed-phase, high performance liquid chromatographic (HPLC) method for the assay of 200-mg troglitazone tablets. The chromatographic conditions of the method employ a YMC ODS-A, 120 A (4.6 x 150 mm, 5 microm) column, isocratic elution with (50 mM aqueous NaH2PO4, pH 4.0):acetonitrile:methanol, (35:50:15, v/v/v) as the mobile phase at a flow rate of 1.0 ml/min, a 10 microl injection volume, and ulltraviolet (UV) detection at 225 nm. The active was analyzed at ambient column temperature, using peak area responses.     

Quantization of Dextromethorphan and Levocetirizine in Combined Dosage form Using a Novel Validated RP-HPLC Method

The present study reveals a simple isocratic RP-HPLC method for the simultaneous determination of dextromethorphan hydrobromide and levocetirizine dihydrochloride in a cough syrup. The separation of these compounds was achieved within 10 min on a Phenomenex (USA) C₁₈ analytical column, 250×4.0 mm i.d., using an isocratic mobile phase consisting of potassium dihydrogen phosphate buffer (pH 2.5) - acetonitrile- tetrahydrofuran (70:25:5, v/v/v). The analysis was performed at a flow rate of 1.2 ml/min and at a detection wavelength of 232 nm. Percentage recovery and RSD were 100.36% and 0.05% for levocetirizine dihydrochloride, 100.35% and 0.27% for dextromethorphan hydrobromide respectively. Quantification of the components in syrup formulation was calculated against the peak areas of freshly prepared standard solutions. The method was validated as per ICH guidelines.     

Rapid and simple high-performance liquid chromatographic determination of felbamate in serum

An isocratic high-performance liquid chromatographic method for the quantitation of felbamate in serum is presented. The method is based on protein precipitation with acetonitrile and reversed-phase chromatography with spectrophotometric detection at 210 nm. The separation was performed on a Nova-Pak C18 column and the mobile phase consisted of acetonitrile-water (1:4, v/v). Phenobarbital was applied as an internal standard. The assay was linear over the concentration range 0.5-200.0 microg/ml (r = 0.9999). Intra-day and inter-day precision expressed by relative standard deviation is less than 3%. The percentage of recovery was 98.63 +/- 2.47. The method is suitable for drug level monitoring and for pharmacokinetic studies.     

Optimization and validation of conventional and micellar LC methods for the analysis of methyltestosterone in sugar-coated pills

Two isocratic liquid chromatographic methods (conventional and micellar) for the determination of methyltestosterone in sugar-coated pills using fluoxymesterone as internal standard have been developed and validated. In conventional liquid chromatography a mobile phase 45% water:acetonitrile 55% (v:v), a flow-rate 1 mlmin(-1) and a C(18) Hypersil ODS (250 x 4.6 mm, 5 microm) column (25 degrees C) were used. In micellar liquid chromatography the conditions were: mobile phase 40 mM sodium dodecyl sulfate: 10% propanol, flow-rate 0.5 mlmin(-1) and C(18) Hypersil ODS (150 x 3.0 mm, 5 microm) column (60 degrees C). For both methods, UV absorbance detection at 245 nm was used and a separation up to base line was achieved. Prior to HPLC analysis a simple sample preparation was required.     

Determination of pinostrobin in rat plasma by LC-MS/MS: application to pharmacokinetics

A rapid and sensitive method for the determination of pinostrobin in rat plasma was developed using liquid chromatography tandem mass spectrometry (LC-MS/MS) for the first time. Isoliquiritigenin was used as an internal standard in rat plasma. Chromatographic separation was performed on an HiQ Sil C₁₈ column with isocratic elution at a flow rate of 1 mL/min. The mobile phase consisted of water and methanol (9:91, v/v) containing 0.1% formic acid. The quantification limit was 10 ng/mL within a linear range of 10-1000 ng/mL (R = 0.9984). The intra- and inter-day assay precision ranged from 3.8-5.3% to 3.2-5.2%, respectively, and the intra- and inter-day assay accuracy was between 93.2-95.1% and 95.5-104.3%, respectively. Our results indicated that the LC-MS/MS method is effective for pharmacokinetic study of pinostrobin in rat plasma.     

Method development and validation for the HPLC assay (potency and related substances) for 20 mg paroxetine tablets

A reversed phase high performance liquid chromatographic (HPLC) method was developed and validated for use as a stability indicating assay (potency and related substances) of paroxetine in paroxetine hydrochloride 20 mg tablets. Assay samples were extracted at a paroxetine concentration of 0.4 mg ml(-1) utilizing mobile phase as the extraction solvent. The chromatographic conditions employed a C18 column (Inertsil, 5 microm, 15 cm x 4.6 mm), isocratic elution with 10 mM 1-decane sulfonic acid sodium salt containing 10 mM sodium phosphate monobasic (pH 3.0)-ACN (60:40, v/v) and ultraviolet (UV) detection at 235 nm.     

Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies

A rapid, simple and sensitive high-performance liquid chromatography (HPLC) method has been developed for quantification of amlodipine in plasma. The assay enables the measurement of amlodipine for therapeutic drug monitoring with a minimum detectable limit of 0.2 ng ml(-1). The method involves simple, one-step extraction procedure and analytical recovery was about 97%. The separation was performed on an analytical 125 x 4.6 mm i.d. Nucleosil C8 column. The wavelength was set at 239 nm. The mobile phase was a mixture of 0.01 M sodium dihydrogen phosphate buffer and acetonitrile (63:37, v/v) adjusted to pH 3.5 at a flow rate of 1.5 ml min(-1). The calibration curve was linear over the concentration range 0.5-16 ng ml(-1). The coefficients of variation for inter-day and intra-day assay were found to be less than 10%.